Summit Therapeutics Share Discussion Threads

[chrisatrdg] 19/5/2017 16:06

Hi All - I am still staying positive & would be surprised if we went down to £1.50 in May or June nor even July but for me Summer ends in August (excluding Indian Summer in Sept)by which time I am expecting a RDZ deal if not share price may well reduce from todays share price

I note we have currently some blue today on AIM & NASDAQ up 7.03% on NLS share vol. of 3,150.

However I do not have a crystal ball but provided the science remains solid still good to hold.

[football] 19/5/2017 09:37

waterloo01 remember we don't have summers here in the UK as we have a nice Thursday afternoon followed by a few days when it doesn't rain

[waterloo01] 19/5/2017 09:35

Don't think they will wait too long before deciding on RDZ (they have said by summer).

Re FDA, if anything SRPT opened the door but be thankful SUMM are doing a larger and more robust study that as Glyn has said in order to make the FDA's decision an easy one! (Assuming it works!).

[tightfist] 19/5/2017 07:45

Thanks Waterloo, I hope this doesn't leave scorched earth in the FDA DMD space when we get there - hopefully!If we don't get newsflow (RDZ please...) or access new money through all those conferences, I can see us drifting back to 150p over the next month or two.

[waterloo01] 17/5/2017 10:02

All decent events but ASM microbe sticks out for me as it's the key event in the sector. Hopefully news at or around this time.

[football] 17/5/2017 09:50

Maybe some news is coming in June seeing most of them are in that month

[chrisatrdg] 17/5/2017 09:48

7 New conferences listed by Summit today looks exciting:

[waterloo01] 17/5/2017 08:55

RDZ next steps can't be far off?

[tightfist] 17/5/2017 08:41

Thanks football, a very concise message from RP. Clearly the market was anticipating no issues with events leading to this successful Milestone.Hopefully there will soon be some unexpected positive developments to move us forward.Cheers, tightfist

[football] 15/5/2017 16:05

Summit Therapeutics to receive US$22mln milestone payment as final patient enrols for DMD trial
Share
12:59 15 May 2017

[luminoso] 15/5/2017 12:46

AIM will take its lead from nasdaq this pm.

[chrisatrdg] 15/5/2017 12:25

Got your drift freedosh would be good to move up to the next level & agree with waterloo01 good that RNS earlier than being suggested by SRPT recent comments.

At present only up 10p per Barclays Stockbrokers 5.63% hopefully more to come - currently share price is 'woefully low'.

[freedosh] 15/5/2017 12:18

Inverted shoulder completed. Should rocket to 250p now.
No advice intended! GLA

[waterloo01] 15/5/2017 12:16

24 wk MRI and function data from all 40 alongside biopsy data from 20 in 1st Q 18. Great to get milestone earlier than expected (based on SRPT comments) and look forward to RDZ update before the summer!

[football] 15/5/2017 12:04

best bit- Summit to Receive $22 Million Milestone Payment

[hugus maximus] 15/5/2017 12:02

Hurrah! RNS Summit to Receive $22 Million Milestone Payment .... SUMMIT COMPLETES ENROLMENT OF PhaseOut DMD, A PHASE 2 CLINICAL TRIAL OF EZUTROMID IN PATIENTS

[luminoso] 14/5/2017 17:08

Shameless, blatant plug - while waiting for news, might be worth casting an eye over N4P, which awoke from its slumber on friday..........I'll get my coat.

[hugus maximus] 12/5/2017 16:52

zzzzZZZZZZ

[football] 12/5/2017 14:45

Can't believe it's over a week without a post here let's hope for some news so we have something to post about

[luminoso] 05/5/2017 13:26

Must have been an advfn glitch, football. Like you, I saw the price was up 5p or so first thing this morning but now no record of it.

[football] 05/5/2017 08:09

news at 12 seeing the share price is up

[chrisatrdg] 04/5/2017 13:35

Recent SEC Submission as per previous years:

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
April 27, 2017

ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES EXCHANGE ACT OF 1934

Summit Therapeutics plc

File No. 001-36866 - CF#34960
_____________________

Summit Therapeutics plc submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 20-F filed on March 30, 2017.

Based on representations by Summit Therapeutics plc that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

Exhibit 4.23 through October 3, 2026
Exhibit 4.24 through December 4, 2017

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields Secretary